A controlled clinical and statistical study of 47 unselected patients with sustained arterial hypertension who received dihydroergocornine intravenously and orally is presented. The study demonstrates the central effect of this drug in temporarily lowering the systolic and diastolic blood pressure and pulse rate. This action occurs irrespective of associated pathology or extent of the hypertensive state when the drug is given parenterally. Orally, little effect was demonstrated.
W D ITH THE advent of surgical palliation,' interest has been renewed in the relationship of the sympathetic nervous system to arterial hypertension. This method of approach has often failed because it does not utilize all of the physiologic components which take part in this syndrome. The neurogenic control of the hypertensive state must include complete interruption of central and peripheral pressor impulses, with analogous activation of the depressors, and an inhibitory effect on the heart rate through the vagus. Earlier investigators2-4 felt that this effect could be accomplished by a chemical agent. Due to the necessity for induced narcosis in animals then under experimental study, the central effect of depressor drugs proved worthless. Investigation5' 6 demonstrated, however, both a peripheral and central rise of arterial blood pressure following the use of various ergot components, and this could be abolished by spinal cord section.' In a few instances ergot derivatives produced a fall in blood pressure," and this fall was found to be due to inhibition of adrenergic function.9 These studies suggested the presence of sympatholytic components in ergot.
During 1943 the various alkaloids of ergot CLINICAL EFFECTS The 12 patients utilized for the control study received their injections with the same technic and clinical follow--up as those receiving dihydroergocornine. No perceptible alterations in blood pressure or pulse rates were observed. These patients subsequently received dihydroergocornine.
The effects of dihydroergocornine given intravenously in a single dose (in amounts indicated in table 1) were generally a reduction of the systolic and diastolic blood pressure and slowing of the pulse. Only in the aged and in a few patients with extreme renal damage was this effect so small as to be inconsequential.
Detailed studies of the results obtained showed that the percentage reduction of the systolic pressure, diastolic pressure, and pulse rate was essentially identical in each patient of this series. Thus, if the systolic pressure fell to 80 per cent of the pretest reading, so also did the diastolic pressure and pulse rate; if one was unaffected so were the other two. In each time interval for two hours following medication these three measurements tended to change simultaneously and equally, provided they were each expressed as a percentage of the pretest level. After twenty-four hours, however, the diastolic pressure had generally returned to the untreated level while the systolic pressure and pulse rate remained slightly reduced. Because of this mode of action it was decided to present the findings in terms of percentages rather than in millimeters of mercury or beats per minute. The systolic pressure at each interval following the injection of dihydroergocornine was therefore expressed as a percentage of the pretest reading and the mean and standard deviation of these percentages for the 47 It can be seen that the blood pressure and pulse readings fell on an average to about 83 per cent of their pretest readings (or were reduced by 17 per cent). Since the individuals were found to be normally distributed about their mean or average (both in the entire group and in the numerous subdivisions which were studied statistically), when arranged arithmetically, it is permissible to utilize the standard deviations shown in the table to estimate the probability that patients of this kind will exhibit a given percentage reduction as a result of similar treatment. For example, one patient out of 6 may be expected from these studies to have a reduction in blood pressure and pulse rate of less than 5 per cent; about one-half should have a reduction of at least 15 per cent; and one in 6 may be expected to show a reduction of 25 per cent or more. In view of the diversity of the group studied and in the findings noted it is not unlikely that these estimations may be good approximations of the effects of dihydroergocornine upon the pulse and blood pressure when administered in a single dose intravenously.
With respect to the possible effect of age upon the percentage reductions in blood pressure and pulse rate, no significant differences were found except in a very small group aged 70 years or more, where the drug had somewhat less effect than in those less than 70 years of age. However, in view of the smallness of the group and the absence of any age differences in the younger group, this finding should receive no undue attention. Similarly it was noted that in the small group of patients with severe renal damage the blood pressure and pulse rates fell somewhat more slowly than was the case in patients with less renal damage, but, this difference was observed only at the first fifteen-minute interval and whether valid or not it would appear to be of little consequence.
With these exceptions, the response to the drug weas not significantly influenced by age, sex, congestive heart failure, cardiac hypertrophy or left axis deviation, arteriosclerosis, angiospasm, degree of renal damage, dosage of the drug, the interval at which it was given, or the pretest level of the pulse or blood pressure when all calculations were based upon percentage change of the postinjection readings in elation to preinjection readings. The large individual variations observed in this series must therefore be ascribed to factors now uinnovn other than those just referred to. Ten patients of this series received dihydroergocornine on two or more subsequent days in dosage varying from 0.25 to 0.5 milligram. In these the reduction of blood pressure and pulse rate was similar to the change that took place in patients receiving the single injection. The oral use of dihydroergocornine failed to produce an appreciable reduction in the blood pressures or pulse rates of this group, irrespective of the dosage given (0.5 mg. to 15 mg. daily). In this group it was administered in both liquid and tablet form.
With respect to the toxic manifestations, 17 of the 47 patients observed in this series had no untoward symptoms. The remaining 30( sbtl-jects exhibited one or more of the effects shown in table 3. It will be noted that a majority of these reactions consisted of a transient "nasal stuffiness" which in no way disturbed the patient. Only in two did we observe toxic manifestations which would be considered "alarming." These recovered spontaneously without additional medication. Definite predictions concerning the frequency of uncommon events cannot reliably be made from samples of this size. It can only be stated at this time that reactions do occur with the doses used. There is no evi- 
DISCUSSION
To be assured that only patients with sustained hypertension were chosen for this preliminary study, a careful historical survey was made on each patient and this was followed by daily clinical observation. Of the first 94 patients with hypertension studied, all but 18 were discarded since rest, induced sedation, and a low-sodium diet effectively lowered their blood pressures and pulse rates. The 47 patients accepted retained an appreciable elevation of their blood pressures after the institution of this regime. The 12 control patients utilized failed to demonstrate an appreciable lowering of the blood pressure or pulse rate yet subsequently the administration of dihydroergocornine intravenously produced an appreciable effect. Two patients included in this series had undergone unsuccessful paravertebral sympathectomies. In both we were able to demonstrate an appreciable reduction of both systolic and diastolic blood pressure and pulse rate following the use of dihydroergocornine. This effect would suggest the possibility of inadequate surgical section.
The data presented here together with evidence cited earlier indicates that dihydroergocornine intravenously has a depressor effect upon the blood pressure and a slowing effect upon the heart rate; that the percentage reduction in systolic pressure, diastolic pressure and pulse rate is the same for any given patient; and that this effect of a single dose is well maintained for at least two hours, and even persists for at least twenty-four hours so far as the systolic pressure and pulse rate are concerned. This result suggests that the hypertensive state in this group was at least partially induced through the action of pressor substances on the sympathetic system and that the vasodilator and vasoconstrictor centers played an important role in this mechanism. Inasmuch as it has been shown that dihydroergocornine acts in the main as a sympatholytic agent, the results obtained support the neurogenic mechanism of this syndrome. The slowing of the pulse is accomplished by the action of this drug on the vagus center. We have demonstrated the abolition of this effect by the administration of atropine to test subjects. The action of dihydroergocornine is unlike that of so-called peripheral vasodilators in common use today. In these, vasodilatation is rapidly followed by cardiac acceleration. This action often produces a subsequent rise in arterial pressure which may increase the load on the heart. Because both a reduction of blood pressure and heart rate may appreciably reduce coronary flow, we feel that the use of dihydroergocornine is contraindicated in the presence of coronary artery disease. Although untoward reactions may occur from its use, these do not appear to be sufficiently frequent or of such severity as to preclude further study.
This drug offers hope as a palliative measure for the treatment of arterial hypertension in as much as its sympatholytic action also embraces a slowing effect on the heart and a minimal cumulative effect.
It is felt that it may prove to be a valuable adjunct in the selection of suitable hypertensive patients for surgical palliation because of its central action and because of our experience with two patients in this series.
